Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Bernicker, Eric H. (PI)
- Darcourt, Jorge (Key Personnel)
- Heyne, Kirk (Key Personnel)
- Singh, Monisha (Key Personnel)
- Templeton, Sandra (Key Personnel)
Project: Clinical Trial